http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0250966-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1282 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G21G4-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate | 1987-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1991-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1991-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0250966-B1 |
| titleOfInvention | Procedure for isolating and purifying radioactive ligated rhenium pharmaceuticals and use thereof and kit |
| abstract | A sterile pyrogen free Re<1><8><6> or Re<1><8><8> radiopharmaceutical is prepared by reducing radioactive perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO2 and free ligand. The radiopharmaceutical is obtained by a low pressure purification method. The solution is added to a separation column (12), preferably an ion exchange column, and a first portion is eluted and discarded. The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO2. This can be used as is to image and treat metastatic bone lesions. A simple kit is also disclosed. |
| priorityDate | 1986-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.